Drug interactions involving the new second- and third-generation antiepileptic drugs

Expert Review of Neurotherapeutics

Volumn 10, Issue 1, 2010, Pages 119-140

  Johannessen Landmark, Cecilie ^b   Patsalos, Philip N ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c EPILEPSY SOCIETY   (United Kingdom)

Author keywords

Interactions; Pharmacodynamics; Pharmacokinetics; Second generation antiepileptic drugs; Third generation antiepileptic drugs

Indexed keywords

ANTACID AGENT; CARBAMAZEPINE; CIMETIDINE; CLOBAZAM; CLONAZEPAM; CONTRACEPTIVE AGENT; ENZYME INDUCING AGENT; ESLICARBAZEPINE ACETATE; ETHINYLESTRADIOL; ETIRACETAM; FELBAMATE; GABAPENTIN; GESTODENE; HARKOSERIDE; LAMOTRIGINE; LEVONORGESTREL; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; WARFARIN; ZONISAMIDE;

ADD ON THERAPY; APATHY; ATAXIA; BENIGN CHILDHOOD EPILEPSY; BLURRED VISION; BONE MARROW TOXICITY; BRAIN DISEASE; COORDINATION DISORDER; DECREASED APPETITE; DIPLOPIA; DISABLING TREMOR; DIZZINESS; DRAVET SYNDROME; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INDUCTION; ENZYME INHIBITION; EPILEPSY; FOCAL EPILEPSY; HEADACHE; HUMAN; HYPERAMMONEMIA; HYPERAMMONEMIC ENCEPHALOPATHY; HYPOTHERMIA; LENNOX GASTAUT SYNDROME; LIVER FAILURE; LIVER METABOLISM; MYOCLONUS EPILEPSY; NAUSEA; NERVOUSNESS; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; WEIGHT REDUCTION;

ANIMALS; ANTICONVULSANTS; DATABASES, FACTUAL; DEPRESSION; DRUG INTERACTIONS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 74949138710     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.136     Document Type: Review

References (122)

1. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther. Drug Monit. 24(1), 91-103 (2002). • Overview with a focus on the new antiepileptic drugs (AEDs) marketed until 2002.
2. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 43(4), 365-385 (2002). •• Comprehensive review of important interactions in epilepsy, with pharmacokinetic parameters and CYP enzyme details and how drug interactions could be managed clinically.
3. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2(6), 347-356 (2003). • Comprehensive review of the mechanisms of drug interactions, with a focus on important interactions between AEDs with therapy guidelines.
4. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2(8), 473-481 (2003). •• Comprehensive review of important interactions between AEDs and other drugs.
5. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 61(3), 246-255 (2006). •• Review of the nature of interactions and the clinical significance regarding alterations in serum concentrations and important interactions between AEDs and other drugs.
6. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N et al. Valproate-ethosuximide combination therapy for refractory absence seizures. Arch. Neurol. 40, 797-802 (1983).
7. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 40(8), 1141-1146 (1999). • Important documentation of the pharmacodynamic interaction between lamotrigine and valproate.
8. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 26, 423-432 (1997). • Important documentation of the pharmacodynamic interaction between lamotrigine and valproate
9. Tsiropoulos I, Gichangi A, Andersen M, Bjerrum L, Gaist D, Hallas J. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol. Scand. 113(6), 405-411 (2006); Erratum in: Acta Neurol. Scand. 114(1), 70 (2006).
10. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997-2005 - a study from The Netherlands. Eur. J. Clin. Pharmacol. 64(10), 1013-1020 (2008).
11. Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia 39(10), 1083-1087 (1998).
12. Crawford P, Lee P. Gender difference in management of epilepsy - what women are hearing. Seizure 8(3), 135-139 (1999).
13. Pack AM, Davis AR, Kritzer J et al. Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity? Epilepsy Behav. 14(4), 640-644 (2009).
14. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 43(Suppl. 2), 37-44 (2002).
15. Mula M. Anticonvulsants - antidepressants pharmacokinetic drug interactions: the role of CYP450 system in psychopharmacology. Curr. Drug Metab. 9, 730-777 (2008).
16. Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population-based study of prescriptions. Epilepsy Res. 87(1), 31-39 (2009).
17. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83(1), 1-43 (2009). •• Latest overview in the splendid series on new AEDs in development, with the latest information on preclinical characteristics, including drug interactions and clinical efficacy data.
18. McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 23(1), 71-79 (2009).
19. Elger C, Halász P, Maia J et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group Phase III study. Epilepsia 50(3), 454-463 (2009).
20. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 4, 88-96 (2007).
21. O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamate-associated fatal acute hepatic necrosis. Neurology 46(5), 1457-1459 (1996).
22. Palmer KJ, McTavish D. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 45(6), 1041-1065 (1993).
23. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem. Res. Toxicol. 10(4), 457-462 (1997).
24. Graves NM, Holmes GB, Fuerst RH, Leppik IE. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 30(2), 225-229 (1989).
25. Wagner ML, Graves NM, Leppik IE et al. The effect of felbamate on valproic acid disposition. Clin. Pharmacol. Ther. 56(5), 494-502 (1994).
26. Reidenberg P, Glue P, Banfield CR et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin. Pharmacol. Ther. 58(3), 279-287 (1995).
27. Albani F, Theodore WH, Washington P et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 32(1), 130-132 (1991).
28. Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther. Drug Monit. 21(6), 604-608 (1999).
29. Wagner ML, Graves NM, Marienau K, Holmes GB, Remmel RP, Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 32(3), 398-406 (1991).
30. Hussein G, Troupin AS, Montouris G. Gabapentin interaction with felbamate. Neurology 47(4), 1106 (1996).
31. Tisdel KA, Israel DS, Kolb KW. Warfarin-felbamate interaction. First report. Ann. Pharmacother. 28, 805 (1994).
32. Saano V, Glue P, Banfield CR et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin. Pharmacol. Ther. 58(5), 523-531 (1995).
33. Rodrigues JP, Edwards DJ, Walters SE et al. Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. Mov. Disord. 20(7), 865-870 (2005).
34. Lean MJ. Gabapentin. Epilepsia 36 (Suppl. 2), S73-S86 (1995).
35. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 40 (2-3), 123-127 (2000).
36. Wymer JP, Simpson J, Sen D et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin. J. Pain 25(5), 376-385 (2009).
37. Doty P, Rudd GD, Stoehr T et al. Lacosamide. Neurotherapeutics 4, 145-148 (2007).
38. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-todose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther. Drug Monit. 21(2), 182-190 (1999).
39. May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther. Drug Monit. 21(2), 175-181 (1999).
40. Anderson GD, Yau MK, Gidal BE et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin. Pharmacol. Ther. 60(2), 145-156 (1996).
41. Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol. 56(4), 299-304 (2000).
42. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 7(2), 163-165 (1988).
43. Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J. Clin. Psychopharmacol. 25(4), 342-348 (2005).
44. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. 61(2), 191-199 (2006).
45. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 61(4), 570-571 (2003). • Provides the first evidence to support the fact that lamotrigine levels are decreased by oral contraceptives.
46. Christensen J, Petrenaite V, Atterman J et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48(3), 484-489 (2007).
47. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 17(2), 199-202 (2008).
48. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 46(9), 1414-1417 (2005).
49. Herzog AG, Blum AS, Farina EL et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 72(10), 911-914 (2009).
50. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 342, 185-186 (1993).
51. Besag FM, Berry DJ, Pool F et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 39(2), 183-187 (1998).
52. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85, 77-85 (2000).
53. Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 47, 1818-1821 (2006).
54. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 48(3), 217-219 (2002).
55. Glauser TA, Pellock JM, Bebin EM et al. Efficacy and safety of levetiracetam in children with partial seizures: an openlabel trial. Epilepsia 43(5), 518-524 (2002).
56. Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A, Yagen B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11- trans-dihydrodiol in human urine. J. Chromatogr. B Biomed. Sci. Appl. 738(2), 419-425 (2000).
57. Tartara A, Galimberti CA, Manni R et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br. J. Clin. Pharmacol. 36(4), 366-368 (1993).
58. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin. Pharmacokinet. 42(12), 1023-1042 (2003).
59. Hossain M, Sallas W, Gasparini M et al. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology 52(Suppl. 2), A525 (1999).
60. McKee PJ, Blacklaw J, Forrest G et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br. J. Clin. Pharmacol. 37(1), 27-32 (1994).
61. Sallas WM, Milosavljev S, D'souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin. Pharmacol. Ther. 74(2), 138-149 (2003).
62. Pisani F, Fazio A, Oteri G et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol. Scand. 90 (2), 130-132 (1994).
63. Fattore C, Cipolla G, Gatti G et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40(6), 783-787 (1999). • Demonstrates the clinically important interaction between oxcarbazepine and oral contraceptives.
64. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45(Suppl. 6), 13-18 (2004).
65. Perucca E, Cloyd J, Critchley D et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49(7), 1123-1141 (2008). •• Comprehensive review on the clinical pharmacokinetics of rufinamide, including data on its interaction potential.
66. Brodie MJ, Rosenfeld WE, Vazquez B et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 50(8), 1899-1909 (2009).
67. Glauser T, Kluger G, Sachdeo R et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70 (21), 1950-1958 (2008).
68. Levy RH, Lin HS, Blehaut HM, Tor JA. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J. Clin. Pharmacol. 23(11-12), 523-533 (1983).
69. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin. Pharmacol. Ther. 36(5), 661-669 (1984).
70. Tran A, Vauzelle-Kervroedan F, Rey E et al. Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children. Eur. J. Clin. Pharmacol. 50(6), 497-500 (1996).
71. Bialer M, Johannessen SI, Kupferberg HJ et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat conference (Eilat VIII). Epilepsy Res. 73, 1-52 (2007).
72. Chiron C. Stiripentol. Neurotherapeutics 4(1), 123-125 (2007).
73. Chiron C, Marchand MC, Tran A et al. Stirpentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 356, 1638-1642 (2000).
74. Pollack MH, Roy-Byrne PP, Van Ameringen M et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry 66 (11), 1401-1408 (2005).
75. Evans KC, Simon NM, Dougherty DD et al. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology 34 (2), 390-398 (2009).
76. Wang X, Patsalos PN. The pharmacokinetic profile of tiagabine. Rev. Contemp. Pharmacother. 12, 225-234 (2002).
77. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 55(3), 437-460 (1998).
78. Langtry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 54(5), 752-773 (1997).
79. Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs 67(15), 2231-2256 (2007).
80. Adín J, Gómez MC, Blanco Y, Herranz JL, Armijo JA. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther. Drug Monit. 26(3), 251-257 (2004).
81. Rosenfeld WE, Liao S, Sica DA et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38, 324-333 (1997).
82. Sachdeo RC, Sachdeo SK, Walker SA et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37(8), 774-780 (1996).
83. Sachdeo RC, Sachdeo SK, Levy RH et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43(7), 691-696 (2002); Erratum in: Epilepsia 43(10), 1273 (2002).
84. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther. Drug Monit. 24(3), 332-337 (2002).
85. Liao S, Plamer M. Digoxin and topiramate drug interaction in male volunteers. Pharm. Res. 10(Suppl.), 405 (1993) (Abstract).
86. Bialer M, Doose DR, Murthy B et al. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43(12), 763-780 (2004).
87. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44(4), 540-549 (2003).
88. Conway M, Cubbidge RP, Hoskings SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 49, 108-116 (2008).
89. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol. Ther. 67(3), 351-384 (1995).
90. Gatti G, Bartoli A, Marchiselli R et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br. J. Clin. Pharmacol. 36(6), 603-606 (1993).
91. Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J. Clin. Pharmacol. 38(2), 166-171 (1998).
92. Ojemann LM, Shastri RA, Wilensky AJ et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther. Drug Monit. 8(3), 293-296 (1986).
93. Fukuoka N, Uno J, Tsukamoto T et al. Dose adjustment of phenytoin for comedication in Japanese patients with epilepsy. Ther. Drug Monit. 31(1), 57-62 (2009).
94. Okumura, K. Decrease in plasma zonisamide concentrations after coadministration of risperidone in a patient with schizophrenia receiving zonisamide therapy. Int. Clin. Psychopharmacol. 14(1), 55 (1999).
95. Johannessen Landmark C, Johannessen SI. Pharmacological management of epilepsy: recent advances and future prospects. Drugs 68(14), 1925-1939 (2008).
96. Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse effect profile of brivaracetam after multiple increasing oral doses in healthy men. Br. J. Clin. Pharmacol. 66, 71-75 (2008).
97. Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-briavaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Dispos. 36, 36-45 (2008).
98. Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse effect profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 63, 680-688 (2007).
99. Otoul C, von Rosenstiel P, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Epilepsia 48(Suppl. 6), 334 (2007) (Abstract).
100. Mannens GS, Hendrickx J, Janssen CG, Chien S et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab. Dispos. 35(4), 554-565 (2007).
101. Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia 47, 1822-1829 (2006).
102. Novak GP, Kelly M, Zannikos P et al. Carisbamate (RWJ-333369). Neurotherapeutics 4, 106-109 (2007).
103. Levy R, Ragueneau-Majlessi I, Solanki B et al. Pharmacokinetics, safety, and tolerability of the new antiepileptic drug carisbamate (RWJ-333369) in the elderly. Epilepsy Res. 79 (1), 22-30 (2008).
104. Chien S, Yao C, Mertens A et al. An interactions study between the new antiepileptic and CNS drug carisbamate (RWJ 333369) and lamotrigine and valproic acid. Epilepsia 48 (7), 1328-1338 (2007).
105. Chien S, Bialer M, Solanki B. et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia 47 (11), 1830-1840 (2007).
106. Parker RJ, Hartman NR, Roecklein BA et al. Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by postmitochondrial suspensions. Chem. Res. Toxicol. 18, 1842-1848 (2005).
107. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol. Rep. 61, 197-216 (2009).
108. Monaghan EP, Navalta LA, Shum L et al. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 38, 1026-1031 (1997).
109. Ferron GM, Patat A, Parks V et al. Lack of pharmacokinetic interactions between retigabine and phenobarbitone at steady-state in healthy subjects. Br. J. Clin. Pharmacol. 56, 39-45 (2003).
110. Hermann R, Knebel NG, Niebch G et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol. 58, 795-802 (2003).
111. Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 4, 149-154 (2007).
112. Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 44, 46-53 (2003).
113. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51, 31-71 (2002).
114. Patsalos PN, Berry DJ, Bourgeois BF et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49(7), 1239-1276 (2008). •• Up-to-date guidelines for therapeutic drug monitoring of AEDs, including indication guidelines with regard to clinical settings whereby polytherapy with interacting drugs occurs.
115. Aguglia U, Barboni G, Battino D, et al. Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia 50(Suppl 1), 7-23 (2009)
116. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38(3), 317-323 (1997).
117. Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 50(4), 1146-1148 (1998).
118. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 43(7), 697-702 (2002).
119. Bockbrader HN, Posvar EL, Hunt T, Randinitis EJ. Pregabalin does not alter the effectiveness of an oral contraceptive. Neurology (Suppl. 5), A314 (2004) (Abstract P04.097).
120. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J. Pharm. Med. 4, 141-150 (1994).
121. Bartoli A, Gatti G, Cipolla G et al. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 38(6), 702-707 (1997).
122. Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin. Ther. 26(12), 2056-2065 (2004).